PL
PLX
Methodology breakdown computing — it will appear here on its own.
Protalix BioTherapeutics Inc. (PLX) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for PLX — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 68.10 | NEUTRAL |
| Stochastic %K (14) | 97.50 | SELL |
| CCI (20) | 110.07 | SELL |
| Williams %R (14) | -2.50 | SELL |
| MACD (12,26,9) | 0.02 | BUY |
| ROC (10) | 10.08 | BUY |
| Momentum (10) | 0.25 | BUY |
| EMA (10) | 2.62 | BUY |
| SMA (10) | 2.62 | BUY |
| EMA (20) | 2.54 | BUY |
| SMA (20) | 2.49 | BUY |
| EMA (30) | 2.50 | BUY |
| SMA (30) | 2.47 | BUY |
| EMA (50) | 2.43 | BUY |
| SMA (50) | 2.42 | BUY |
| EMA (100) | 2.35 | BUY |
| SMA (100) | 2.25 | BUY |
| EMA (200) | 2.29 | BUY |
| SMA (200) | 2.26 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Protalix BioTherapeutics Inc.
Healthcare · Biotechnology
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | BULLISH | 37 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.